MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

Why is Eli Lilly Betting on Shingles Vaccines

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Why is Eli Lilly Betting Big on Orforglipron with a $1.5 Billion Inventory

4 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

3 months ago

What's Driving the Bearish Options Activity in Eli Lilly

4 months ago

Is Eli Lilly's Aggressive Genetic Medicine Push a Game Changer

1 months ago

3 Reasons Eli Lilly Remains a Buy

Eli Lilly shares rose more than 13% year-to-date, driven by multiple growth catalysts. The pharmaceutical company maintains positive momentum as investors weigh several factors that could potentially ...

News•1 months ago

The Ebola Epidemic Is Spreading

Eli Lilly has entered into a trio of vaccine deals as the Ebola epidemic continues to spread. These partnerships arrive as health investors monitor the evolving outbreak and its potential impact on th...

Stock News•1 months ago

Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine

Eli Lilly agreed to acquire a Bothell, Washington-based biotech firm for $1.5B to expand its vaccine pipeline. The deal focuses on developing a next-generation shingles vaccine, marking a significant ...

LLY

Stock News•2 months ago

Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Pfizer and Eli Lilly reported divergent quarterly results, highlighting contrasting strategic paths in pharmaceutical M&A. The performance gap underscores how differing acquisition strategies and prod...

PFE